BioAge Labs announces it will present new preclinical data on APJ agonism
BioAge Labs (BIOA) announced that it will present new preclinical data supporting apelin receptor, APJ, agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction. The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20-23, 2025, in Chicago, Illinois. In their two presentations, the company will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Enhanced glycemic control in diabetic obesity – Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. Cardioprotective effects in HFpEF – Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Healthy.io, Geisinger and Boehringer Ingelheim Study Reveals Significant Increase in Albuminuria Identification with the Addition of Smartphone Technology
Longitudinal data highlight the significant impact of adding a novel home screening test to standard lab testing, increasing opportunities for earlier identification of disease and disease management. BOSTON, June 20, 2025 /PRNewswire/ -- a leader in transforming the smartphone camera into a medical device, Geisinger, one of the nation's leading providers of value-based care, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced data demonstrating the longitudinal impact of a novel chronic kidney disease (CKD) screening pilot program. The study, supported by Boehringer Ingelheim, included 4,000 patients from Geisinger with diabetes and/or hypertension, two prominent risk factors for CKD. Patients in the pilot group received either Minuteful Kidney™ smartphone-powered urine albumin-to-creatinine ratio (uACR) home test or a standard laboratory test, accompanied by patient outreach. The pilot group was compared to a 1:1 propensity-score-matched control group that received usual care (standard, routine healthcare services). Previously reported results revealed a significant 2.5-fold increase in uACR completion rates (53.1% vs. 21.2%, p<0.001) in the pilot group vs. control group. Findings presented at the American Diabetes Association (ADA) 85th Scientific Sessions on June 20, 2025, demonstrate that over a 270-day follow-up period, patients in the pilot group were more likely to receive a diagnosis related to CKD or proteinuria than those in the usual care arm (4.7% vs. 2.9%, p<0.001). Based on results of the Minuteful Kidney™ test, individuals with an elevated uACR (≥30 mg/g) were more likely to complete a primary care follow-up visit (95.3% vs. 92.9%, p<0.001) or a nephrology visit (7.2% vs. 1.7%, p<0.001) compared to those with a normal uACR (< 30 mg/g). Additionally, there were a higher proportion of new ACEi/ARB prescriptions (7.5% vs. 4.4%, p=0.024) or new SGLT2i prescriptions (4.1% vs. 2.7%, p=0.054) for individuals with elevated uACR (≥30 mg/g) compared to those with uACR <30mg/g, indicating the importance of identifying albuminuria. "Closing the uACR testing gap by reaching untested at-risk populations remains a top priority," said Geoff Martin, CEO of "These study results demonstrate how smartphone-enabled testing and education can enhance CKD screening compliance, which ultimately has the potential to improve patient outcomes. We value the collaboration with Geisinger and Boehringer Ingelheim as we work to close a care gap by supporting earlier identification of CKD through screening those identified as at risk of disease." "Detecting CKD early is crucial, as timely intervention can help mitigate the risk of disease progression and cardiovascular complications," said Brian DiDonato, Senior Vice President, Cardio-Renal-Metabolic Brands at Boehringer Ingelheim. "We are proud to support this important study of Minuteful Kidney program, which presents an innovative approach to address the urgent need for enhanced CKD screening." "uACR testing is critical for evaluating kidney health and risk of cardiovascular events such as myocardial infarction or stroke," said Alexander Chang, M.D., MS, Associate Professor from the Department of Population Health Sciences at Geisinger. "Given the increased rates of engagement, testing and follow-up care shown in this study, we are excited about the potential for the Minuteful Kidney program to drive earlier diagnosis rates and help make a direct, positive impact on patients' lives." Limited awareness of, and access to, comprehensive screenings often contribute to poorer outcomes, emphasizing the urgent need for innovative solutions. Minuteful Kidney is the only FDA-cleared, smartphone-enabled home uACR test for CKD, allowing patients to receive clinical-grade results within minutes. As a part of the pilot program, participants in the pilot group received education via the engagement team. For those completing the Minuteful Kidney test, the associated app provided additional education regarding testing and supported follow-up and results sharing with healthcare providers. The pilot program demonstrated how a home testing approach can complement and help remove barriers to care. About CKD CKD is a national health crisis that affects more than 35 million U.S. adults, increasing their risk for cardiovascular (CV) disease, kidney failure and dialysis. Yet approximately 90% of those with CKD are unaware that they have it, as it often has no symptoms until it progresses to more advanced stages. Clinical guidelines recommend routine screenings for at-risk individuals using both estimated glomerular filtration rate (eGFR) and uACR tests; however, broad adoption of these guidelines remains low. This testing gap hinders early detection of both kidney dysfunction and CV risk, as elevated uACR is associated with an increased risk of CV events, including myocardial infarction, stroke, hospitalization for heart failure and CV death. About transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company's at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. is a global leader in digital health and is a recipient of the 2023 MedTech Breakthrough 'Best In-Home Testing Solution' Award and the Juniper Research's Digital Health Innovation 'Best Digital Diagnostics Solution' 2023 Award. The company has offices in Boston, London and Tel-Aviv. About Geisinger Geisinger is among the nation's leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the nonprofit system generates $10 billion in annual revenues across 126 care sites — including 10 hospital campuses — and Geisinger Health Plan, with more than half a million members in commercial and government plans. Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,700 employed physicians, Geisinger is among Pennsylvania's largest employers with an estimated economic impact of $15 billion to the state's economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country. Learn more at or follow on Facebook, Instagram, LinkedIn and X. About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Media Contact - info@ Logo - View original content to download multimedia: SOURCE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
17 hours ago
- Gizmodo
This Once-a-Month Ozempic Rival Just Delivered Big Results
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves once each week. In newly released clinical trial data, Amgen's once-monthly experimental drug MariTide performed as well as or even better than the existing blockbuster GLP-1 medications semaglutide and tirzepatide. People taking MariTide consistently lost more weight than those on placebo, with some losing up to 20% of their baseline weight over a year's time. Amgen is moving ahead to Phase III trials of MariTide, setting the stage for a fierce competition among the next generation of obesity drugs. Amgen presented the full results of its Phase II trial of MariTide this week at the annual American Diabetes Association meeting; the results were also published in the New England Journal of Medicine. Ozempic Might Be a Dementia Buster, Too Like semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro) before it, MariTide mimics GLP-1, a hormone important to regulating our hunger and blood sugar. But the injectable medication has a few new tricks up its sleeve. The drug additionally carries a molecule that targets GIP, another important hunger-related hormone. Interestingly enough, tirzepatide mimics GIP, but MariTide inhibits it (that suggests GIP's role in controlling our weight is plenty complicated). The experimental drug also contains a lab-made antibody designed to keep it lingering in our system for a long time, so it's intended to be taken monthly or once every two months, compared to the weekly shots needed for semaglutide and tirzepatide. The Phase II trial involved nearly 600 adults, some of whom had type 2 diabetes and others with only obesity. In those with obesity only, people lost up to 20% of their weight on average over a 52-week span (those on placebo lost an average of 2.6% body weight). People with type 2 diabetes lost on average up to 17% of their weight. These results, while not directly comparable at this point, are on par with the clinical trial data of the latest GLP-1 drugs. And since participants were still continuing to shed pounds by the study's end, it's possible that the typical weight loss seen with MariTide might be even higher. 'MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week Phase 2 study and meaningful improvements in cardiometabolic risk factors, representing a defining advance for the obesity field,' said Jay Bradner, executive vice president of research and development at Amgen, in a statement from the company. Not everything with MariTide is sunshine and puppies, however. Rates of vomiting were much higher among certain groups of people on MariTide, for instance, which likely contributed to a higher rate of people dropping out before the study's end. But some data also suggest this side effect can be dampened by gradually raising people's doses over time, similar to how existing GLP-1 drugs are managed. The Best Obesity Drugs Aren't Even Here Yet Amgen will fully test out this staggered dosing strategy in its Phase III 72-week-long trial of MariTide for people with obesity and Type 2 diabetes, which has already begun enrollment. The company also plans to launch Phase III trials for cardiovascular disease, sleep apnea, and heart failure. But it's far from alone in the arms race to develop more effective or practical obesity treatments. Dozens of other candidates are in the pipeline, each with their own possible advantages over today's drugs, such as being available via a pill or coming without the gastrointestinal side effects common to GLP-1s. Not all of these experimental drugs will work out, of course, but it seems likely that semaglutide and tirzepatide soon won't be the only options available for people with obesity.
Yahoo
18 hours ago
- Yahoo
‘New era in astronomy.' Penn State helps develop world's most powerful survey telescope
Professors at Penn State helped develop the world's most powerful survey telescope, which released its first images earlier this week from the Vera C. Rubin Observatory in Chile. The images capture cosmic phenomena at an 'unprecedented scale,' the observatory said in a press release. For the next 10 years, the observatory will conduct the 'Legacy Survey of Space and Time,' an international project to create an ultra-wide, ultra-high-definition time lapse record of the universe, a release from Penn State says. The university has been an LSST member institution since 2005, and faculty members have had roles on the LSST board and other committees and collaborations. Donald Schneider, distinguished professor of astronomy and astrophysics at Penn State and the university's representative on the LSST-Discovery Alliance Institutional Board, has been interested in this project since he first heard about it around 2000. J. Anthony Tyson, now the Rubin Observatory LSST chief scientist, came up with the general concept of a telescope that could take deep pictures of the entire sky every night to look for things that moved, changed in brightness, and other aspects, Schneider told the CDT. Penn State joined the collaboration and had roles in both the science collaboration and in project management, he said. The Rubin Observatory on the Cerro Pachón mountaintop in Chile uses a 3,200-megapixel camera the size of a car to scan the entire visible southern sky every three to four nights. 'The sky will be imaged in six different filters covering the range from blue to near-infrared light. By stitching the resulting clips together, the LSST collaboration will produce the most detailed time-lapse view of the cosmos that has ever existed,' the university said in a release. W. Niel Brandt, the Eberly Family Chair in Astronomy and Astrophysics (and professor of physics at Penn State and co-chair of the LSST Active Galactic Nuclei Science Collaboration), said in a release between the impressive camera and the wide field of view, the Rubin Observatory will 'launch a new era in astronomy.' It will allow them to better detect real-time changes in the sky and rare events, he said. Schneider said the telescope has a large mirror, about 320 inches across, so it can gather a lot of light and detect very faint objects over a large part of the sky. 'You've heard of the James Webb and the Hubble Space Telescope, they can go very deep. They can actually go deeper than the Rubin telescope can, but only over a tiny fraction of the area,' he told the CDT. 'So, when the Rubin takes a picture, it takes 45 full moons. … Every time it takes a picture, it takes that much sky. With the Hubble Space telescope or the James Webb, it's just a tiny fraction of the moon that they can take a picture of.' The first pictures released on Monday were 'spectacular,' Schneider said. Looking at a picture on your TV or computer screen doesn't give the full effect because there aren't enough pixels, so the image is super compressed. 'It's just so compressed, there aren't enough pixels on the TV to show what the picture does. They're 3.2 billion pixels … your eye just can't grasp it, and the TV just can't display it. You need something the size of a basketball court to display it,' he said. 'It takes seven of those pictures every minute throughout the night, so you can imagine how many basketball courts you would have to rent in order to display a night's worth of data.' The facility is jointly funded by the U.S. National Science Foundation and the U.S. Department of Energy's Office of Science. Brian Stone, performing the duties of the NSF director, said in a press release the Rubin Observatory will 'capture more information about the universe than all optical telescopes throughout history combined.' The telescope was designed with many science programs, but one that may be particularly interesting to the public is about near-earth asteroids. Schneider said they know where the big asteroids are, but there are still rocks out there that he thinks are the size of a football field or larger. If one of those hits earth, it would be a bad situation, so Schneider said they need to be able to track them so they can find them early and adjust their orbits. When the first images from the telescope were released this week, he said one thing that impressed him the most was a chart that showed all of the new asteroids they discovered from just one picture. The data gathered during the survey will be public, so you don't need to be a professional astronomer to learn from the project. 'There's a great opportunity for amateur astronomers, or just people that are casually interested in astronomy, or high schools, for example,' he said. 'It would be great lab experiments. You know, you get your part of the sky, what's there? What's interesting? So I'm very excited by this opportunity.'
